Continuing Education Activity

Chikungunya virus (CHIKV) is an emerging arthropod-borne alphavirus transmitted by Aedes mosquitoes that causes an acute febrile illness marked by severe polyarthralgia, rash, and potential progression to chronic inflammatory arthritis with long-term morbidity. Since its expansion from Africa and Asia to the Americas and other regions, CHIKV has become a significant global public health concern, driven by viral mutations, efficient mosquito vectors, and increased international travel. This course reviews the challenges of clinical diagnosis due to overlapping features with dengue and Zika infections, requiring appropriate laboratory confirmation as well as the recommended management approach, which remains largely supportive, with attention to pain control and avoidance of nonsteroidal anti-inflammatory drugs until dengue is excluded. Participants will also gain an understanding of the chronic manifestations of CHIKV that may require immunomodulatory therapy and the integration of preventive measures, including vaccination and vector control, to reduce disease burden and complications. This activity for healthcare professionals is designed to enhance the learner's competence in identifying CHIKV, performing the recommended evaluation, addressing complications, and implementing an appropriate interprofessional approach when managing this condition. 

Objectives:

• Identify the key clinical features associated with both types of chikungunya virus infection.
• Assess the appropriate diagnostic evaluation per guidelines to confirm a diagnosis of chikungunya fever.
• Implement evidence-based management strategies for the chronic manifestations of chikungunya fever.
• Coordinate interprofessional care strategies to improve outcomes and patient education in regions affected by chikungunya outbreaks.

Introduction

Chikungunya virus (CHIKV) is an arthropod-borne alphavirus belonging to the family Togaviridae, primarily transmitted by Aedes mosquitoes. CHIKV causes an acute febrile illness characterized by high fever, rash, and severe polyarthralgia, commonly known as chikungunya fever, which can progress to chronic, debilitating arthritic symptoms lasting months to years.[1][2] Originally isolated from the Makonde Plateau in Tanzania in 1952, the virus's name derives from a Makonde phrase meaning "that which bends up," describing the stooped posture of afflicted patients.[2] Historically restricted to Africa and Asia, CHIKV’s global presence expanded significantly following the massive outbreak in Reunion Island in 2005 and 2006, which affected approximately 35% of the population.[3] Since 2013, the virus has spread across the Americas via the Caribbean island of St. Martin, resulting in widespread transmission in tropical and subtropical regions worldwide, posing a significant public health concern.[4][5][6]

Etiology

Both Aedes aegypti and Aedes albopictus (Asian tiger mosquito) mosquitoes transmit CHIKV and exhibit high vector competence and capacity, facilitating viral spread.[7][8] Vector competence refers to the mosquito’s biological ability to ingest the virus and support its replication and transmission. In contrast, vectorial capacity encompasses factors, eg, mosquito density, survival, feeding behavior, and the extrinsic incubation period.[9] Ae aegypti has been present in the United States for over 300 years, whereas experts report the first appearance of Ae albopictus in 1985.

A key adaptation occurred during the 2005 to 2006 Indian Ocean outbreak, when CHIKV acquired a mutation in the E1 envelope protein, enhancing its fitness for Ae albopictus and increasing its transmissibility. This mutation expanded CHIKV's geographic range by enabling infection via a more widely distributed mosquito vector.[8] Human travel and trade have further contributed to the spread of infected mosquitoes and the virus, complicating control efforts.[10] 

Epidemiology

After its discovery in Tanzania, CHIKV maintained an endemic sylvatic cycle in Africa before causing major outbreaks in Asia and the Indian Ocean region.[11] The first confirmed introduction into the Americas was reported in the Caribbean in 2013, with local transmission in Florida detected in 2014.[3][4] The virus rapidly spread across the Caribbean islands and Central and South America, facilitated by infected travelers and the widespread presence of competent Aedes vectors.[5] 

Mosquito eggs and larvae have also been transported by shipping and air traffic to new regions, contributing to the establishment of invasive vector populations.[2] While transmission is predominantly mosquito-borne, vertical maternal-fetal transmission and transmission through blood products have been documented, especially during outbreaks, eg, the Reunion Island epidemic.[12][13] Coinfection with other arboviruses transmitted by Ae aegypti and Ae albopictus, eg, Dengue (DENV) and Zika (ZIKV) viruses, presents diagnostic and therapeutic challenges due to overlapping clinical presentations and geographic distributions.[14]

Pathophysiology

CHIKV transmission occurs via 2 cycles: an urban cycle involving human-mosquito-human transmission, predominant in the Americas, and a sylvatic cycle involving non-human primates and mosquitoes in Africa. The aforementioned mutation in the E1 protein enhances viral fitness in Ae albopictus, facilitating the expansion of the urban cycle.[6][15] After inoculation via a mosquito bite, CHIKV infects human epithelial and endothelial cells, fibroblasts, and monocyte-derived macrophages.[16][17] 

The virus disseminates through the lymphatic system and bloodstream, resulting in high-level viremia and seeding of target organs, including muscles, joints, liver, and the central nervous system.[16][18] The acute symptoms are mediated by robust inflammatory responses, initially involving CD8+ T cells, later CD4+ T cells, and proinflammatory cytokines.[19] Persistent infection of monocyte-derived macrophages in joint tissues is hypothesized to underlie chronic arthritis and polyarthralgia.[9][19] 

Histopathology

CHIKV is a positive-sense, single-stranded RNA alphavirus comprising 3 genotypes: Asian, West African, and East-Central-South African.[20] The virus is thermolabile, sensitive to temperatures above 58 °C, which limits its environmental persistence outside the vector and host.[6] Histopathological studies of affected joint tissues show chronic synovitis characterized by macrophage infiltration and inflammatory cytokine expression, correlating with clinical joint pain and swelling.[9]

History and Physical

After a 3- to 7-day incubation period, patients typically develop sudden high-grade fever, severe bilateral symmetrical polyarthralgia, and myalgia.[1][11][21] Joint involvement preferentially affects distal joints, especially the hands, wrists, ankles, and knees, and is often accompanied by intense pain lasting 1 to 3 weeks. However, symptoms may persist longer.[21][22] A generalized maculopapular rash typically appears approximately 3 days after fever onset, initially involving the extremities and sometimes spreading to the trunk.[23] Less commonly, vesiculobullous and mucocutaneous lesions are reported.[23][24]

Other systemic symptoms include headache, abdominal pain, diarrhea, vomiting, and generalized lymphadenopathy. Although not primarily neurotropic, patients with a CHIKV infection may experience neurologic complications, notably neonatal encephalitis from vertical transmission.[3][25] Ocular manifestations, eg, conjunctivitis, anterior uveitis, iridocyclitis, and retinitis, are possible, and patients in endemic regions may experience recurrent ocular inflammation.[26][27][28][29] 

Evaluation

The diagnosis of CHIKV infection is primarily clinical in endemic areas or following travel to affected regions, with fever and polyarthralgia having a sensitivity of 84%, a positive predictive value (PPV) of 71%, and a negative predictive value (NPV) of 83%.[30] However, coexisting circulation with DENV and ZIKV complicates clinical diagnosis due to overlapping symptoms.[31] Laboratory confirmation relies on detection of viral RNA via reverse transcription polymerase chain reaction (RT-PCR) during the acute phase (first 5 days of illness) or serologic detection of virus-specific IgM and IgG antibodies using ELISA or indirect immunofluorescence assays thereafter.[32][33][34] The CDC recommends simultaneous testing for CHIKV, DENV, and ZIKV in suspected cases to identify coinfections.[35] Lymphopenia and thrombocytopenia may be seen on laboratory evaluation.

Treatment / Management

Currently, no widely available antiviral therapy exists for CHIKV infection, and management remains primarily supportive.[17][36] Treatment focuses on adequate hydration, rest, and pain control, typically with acetaminophen. Clinicians should avoid NSAIDs and aspirin until they exclude DENV infection due to the risk of hemorrhagic complications.[36] Please see StatPearls' companion topic, "Dengue Fever," for an in-depth discussion of the presentation, evaluation, and treatment of dengue fever. In the post-acute and chronic phases, corticosteroids and disease-modifying antirheumatic drugs (DMARDs), eg, hydroxychloroquine, may be used to manage persistent inflammatory arthritis. Ocular complications have been treated successfully with topical corticosteroids and cycloplegics.[37] Experimental therapies, including siRNA-based antivirals, are under investigation but are not yet in routine clinical use.[38][39][40]

Preventive strategies focus on vector control and personal protection, including the use of insect repellents (eg, DEET), protective clothing, bed nets, and the elimination of mosquito breeding sites.[41][42] Clinicians and public health teams commonly use insecticides (eg, pyrethroids and organophosphates), although increasing resistance remains a growing concern.[43] Currently, 2 chikungunya vaccines have been developed. The recombinant chikungunya virus vaccine, or virus-like particle (VLP) vaccine, is approved by both the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for patients aged 12 years and older.

The live-attenuated chikungunya virus vaccine is only approved by the EMA, as the FDA withdrew approval due to the risk of adverse events. The Advisory Committee on Immunization Practices (ACIP) recommends vaccination for people traveling to areas with chikungunya outbreaks or planning travel of 6 months or longer to a country with elevated risk.[44][45] Additional candidates for vaccination are laboratory workers at risk of exposure to the chikungunya virus.

Differential Diagnosis

Given the nonspecific presentation of fever, arthralgia, and rash, the differential diagnosis for both acute and chronic manifestations of chikungunya fever is broad. DENV and ZIKV share similar clinical features and are transmitted by the same Aedes mosquito, often prompting evaluation for all 3 infections based on clinical context and local epidemiology.[35] Other infectious causes to consider include the following:

• Malaria
• Yellow fever
• Leptospirosis
• Measles
• Mononucleosis
• African tick bite fever
• Ross River virus
• Oropouche virus 

Chronic chikungunya-associated arthralgia can mimic more common rheumatologic conditions and may be difficult to distinguish clinically. Additionally, patients with preexisting joint disease who develop CHIKV infection may experience more severe symptoms and increased morbidity.[46] The differential diagnosis for chronic manifestations includes the following:

• Seronegative rheumatoid arthritis
• Rheumatoid arthritis 
• Hepatitis C
• Systemic lupus erythematosus
• Reactive arthritis

Prognosis

While CHIKV infection has a low case fatality ratio, this virus is associated with substantial morbidity due to chronic polyarthralgia and arthritis persisting beyond 6 weeks postinfection.[47][48] Studies from Aruba and French Guiana have reported chronic rheumatic symptoms in 26% to 40% of confirmed cases, respectively, at 3 to 6 months.[46][49] Older age and preexisting joint disease increase the risk of severe chronic manifestations.[50][51]

Complications

The most common chronic manifestation of CHIKV infection is persistent inflammatory arthritis characterized by recurrent or prolonged joint pain and swelling, which may last for months to years and, in some cases, require rheumatologic evaluation and treatment. Patients with preexisting joint disease may experience more severe symptoms and increased morbidity. Ocular complications include conjunctivitis, iridocyclitis, episcleritis, optic neuritis, and retinitis. These manifestations are often self-limited but can occasionally result in vision impairment and may require targeted therapy.[28][29]

Additionally, neurologic complications are less common but can be severe, particularly in vulnerable populations, eg, older adults and immunocompromised individuals. Reported complications include encephalitis and Guillain-Barré syndrome.[25] Although most patients recover fully, these complications highlight the potential for significant long-term morbidity and underscore the importance of early recognition and appropriate management.[50][52] 

Consultations

Due to the complex and chronic nature of post-CHIKV arthritis, rheumatology consultation is often necessary for management of persistent joint symptoms. Patients presenting with ocular signs or symptoms should undergo ophthalmology evaluation to prevent long-term sequelae.[50]

Deterrence and Patient Education

Effective mosquito avoidance and vector control are the best preventive measures for CHIKV infection, as no widely accessible curative therapy exists and treatment is primarily supportive. Healthcare professionals play a critical role in educating patients, especially travelers, pregnant individuals, older adults, and those with comorbidities, about risk-reduction strategies. Clinicians should advise patients to use EPA-registered insect repellents (eg, DEET), wear long-sleeved clothing, and use permethrin-treated garments when appropriate. Furthermore, because Aedes mosquitoes bite during the day, clinicians should emphasize protection during daylight hours as well as at dawn and dusk. Additional measures include staying in air-conditioned or well-screened environments, using bed nets when necessary, and eliminating standing water around homes to reduce breeding sites.

Clinicians should counsel patients with suspected or confirmed CHIKV infection to continue mosquito precautions during the first week of illness to prevent further transmission. Education should also include guidance on symptom management, hydration, and appropriate medication use, including avoidance of NSAIDs until after excluding dengue as a potential cause of the patient's symptoms. For patients with persistent joint symptoms, clinicians should set expectations for a prolonged recovery and discuss follow-up care. Clear communication, culturally appropriate education, and coordination with public health resources are essential to reducing transmission risk and improving patient outcomes.

Pearls and Other Issues

The following factors should be kept in mind when managing CHIKV:

• CHIKV is an arthropod-borne alphavirus transmitted primarily by Ae aegypti and Ae albopictus mosquitoes, prevalent in tropical and subtropical climates.[1][8]
• Two vaccines are available, but only to those at significant risk of acquiring the disease, as the live-virus vaccine has notable adverse effects and has been withdrawn in the United States. Those living and working in high-risk areas for more than 6 months of the year, and other select groups, eg, researchers, can consider the risks and benefits of vaccination with the live-virus vaccine. The recombinant vaccine is approved by both the FDA and EMA for those older than 12 years with risk factors for acquiring the disease.[44][45]
• Coinfection with DENV and ZIKV viruses complicates diagnosis and management due to overlapping symptoms and shared vectors.[14][35]
• Acute symptoms include high fever, polyarthralgia, rash, myalgia, and headache, while chronic arthritis is the most disabling complication.[1][21][47] 
• Diagnosis relies on clinical suspicion confirmed by RT-PCR in early disease or serology later; simultaneous testing for other arboviruses is recommended.[32][35] 
• Supportive care remains the cornerstone of treatment; no specific antivirals are currently approved.[36][53][54] 
• Prevention through vector control and personal protective measures is paramount to limit disease spread.[41][42] 
• Chikungunya fever is nationally notifiable to the CDC and monitored closely by global health agencies.[6][18] 

Enhancing Healthcare Team Outcomes

Chikungunya fever is a mosquito-borne viral illness caused by the CHIKV and transmitted primarily by Aedes mosquitoes. It typically presents with an acute febrile illness characterized by severe polyarthralgia, rash, and fatigue, with joint symptoms that may persist for months to years in some patients. Although mortality is low, the disease can cause significant morbidity, particularly in older adults and those with underlying medical conditions. Diagnosis is based on clinical presentation and confirmed with molecular or serologic testing, while management remains largely supportive, focusing on symptom control and prevention of complications.

Effective management of chikungunya fever requires coordinated interprofessional care to optimize patient outcomes and safety. Physicians and advanced practitioners play a central role in diagnosis, risk stratification, and management planning, including distinguishing CHIKV infection from other arboviral illnesses. Nurses contribute through patient monitoring, symptom management, and education on hydration, medication use, and vector prevention strategies. Pharmacists support safe and appropriate medication selection, particularly in avoiding NSAIDs until dengue has been excluded, and assisting with the management of chronic arthralgia. Collaboration with specialists in rheumatology and ophthalmology may be necessary for patients with persistent or complicated disease. Clear communication among team members and with public health authorities enhances surveillance, outbreak response, and patient education, ultimately improving patient-centered care, reducing complications, and strengthening overall healthcare team performance.

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Horwood PF, Buchy P. Chikungunya. Rev Sci Tech. 2015 Aug;34(2):479-89. [PubMed: 26601450]

2.

Paupy C, Delatte H, Bagny L, Corbel V, Fontenille D. Aedes albopictus, an arbovirus vector: from the darkness to the light. Microbes Infect. 2009 Dec;11(14-15):1177-85. [PubMed: 19450706]

3.

Weaver SC, Forrester NL. Chikungunya: Evolutionary history and recent epidemic spread. Antiviral Res. 2015 Aug;120:32-9. [PubMed: 25979669]

4.

Rougeron V, Sam IC, Caron M, Nkoghe D, Leroy E, Roques P. Chikungunya, a paradigm of neglected tropical disease that emerged to be a new health global risk. J Clin Virol. 2015 Mar;64:144-52. [PubMed: 25453326]

5.

Pialoux G, Gaüzère BA, Jauréguiberry S, Strobel M. Chikungunya, an epidemic arbovirosis. Lancet Infect Dis. 2007 May;7(5):319-27. [PubMed: 17448935]

6.

Ganesan VK, Duan B, Reid SP. Chikungunya Virus: Pathophysiology, Mechanism, and Modeling. Viruses. 2017 Dec 01;9(12) [PMC free article: PMC5744143] [PubMed: 29194359]

7.

Fernández-Salas I, Danis-Lozano R, Casas-Martínez M, Ulloa A, Bond JG, Marina CF, Lopez-Ordóñez T, Elizondo-Quiroga A, Torres-Monzón JA, Díaz-González EE. Historical inability to control Aedes aegypti as a main contributor of fast dispersal of chikungunya outbreaks in Latin America. Antiviral Res. 2015 Dec;124:30-42. [PubMed: 26518229]

8.

Higgs S, Vanlandingham D. Chikungunya virus and its mosquito vectors. Vector Borne Zoonotic Dis. 2015 Apr;15(4):231-40. [PubMed: 25674945]

9.

Kramer LD, Ciota AT. Dissecting vectorial capacity for mosquito-borne viruses. Curr Opin Virol. 2015 Dec;15:112-8. [PMC free article: PMC4688158] [PubMed: 26569343]

10.

Lounibos LP, Kramer LD. Invasiveness of Aedes aegypti and Aedes albopictus and Vectorial Capacity for Chikungunya Virus. J Infect Dis. 2016 Dec 15;214(suppl 5):S453-S458. [PMC free article: PMC5137242] [PubMed: 27920173]

11.

de Lima Cavalcanti TYV, Pereira MR, de Paula SO, Franca RFO. A Review on Chikungunya Virus Epidemiology, Pathogenesis and Current Vaccine Development. Viruses. 2022 May 05;14(5) [PMC free article: PMC9147731] [PubMed: 35632709]

12.

Renault P, Balleydier E, D'Ortenzio E, Bâville M, Filleul L. Epidemiology of Chikungunya infection on Reunion Island, Mayotte, and neighboring countries. Med Mal Infect. 2012 Mar;42(3):93-101. [PubMed: 22280563]

13.

Contopoulos-Ioannidis D, Newman-Lindsay S, Chow C, LaBeaud AD. Mother-to-child transmission of Chikungunya virus: A systematic review and meta-analysis. PLoS Negl Trop Dis. 2018 Jun;12(6):e0006510. [PMC free article: PMC6075784] [PubMed: 29897898]

14.

Singh J, Dinkar A, Singh RG, Siddiqui MS, Sinha N, Singh SK. Clinical profile of dengue fever and coinfection with chikungunya. Tzu Chi Med J. 2018 Jul-Sep;30(3):158-164. [PMC free article: PMC6047329] [PubMed: 30069124]

15.

Lum FM, Ng LF. Cellular and molecular mechanisms of chikungunya pathogenesis. Antiviral Res. 2015 Aug;120:165-74. [PubMed: 26092642]

16.

Sourisseau M, Schilte C, Casartelli N, Trouillet C, Guivel-Benhassine F, Rudnicka D, Sol-Foulon N, Le Roux K, Prevost MC, Fsihi H, Frenkiel MP, Blanchet F, Afonso PV, Ceccaldi PE, Ozden S, Gessain A, Schuffenecker I, Verhasselt B, Zamborlini A, Saïb A, Rey FA, Arenzana-Seisdedos F, Desprès P, Michault A, Albert ML, Schwartz O. Characterization of reemerging chikungunya virus. PLoS Pathog. 2007 Jun;3(6):e89. [PMC free article: PMC1904475] [PubMed: 17604450]

17.

Sun W, Shi S, Liao S, Zhai M. Chikungunya fever: pathogenesis and mechanisms underlying pain symptoms. Front Immunol. 2025;16:1679385. [PMC free article: PMC12643972] [PubMed: 41306980]

18.

Kam YW, Ong EK, Rénia L, Tong JC, Ng LF. Immuno-biology of Chikungunya and implications for disease intervention. Microbes Infect. 2009 Dec;11(14-15):1186-96. [PubMed: 19737625]

19.

Chow A, Her Z, Ong EK, Chen JM, Dimatatac F, Kwek DJ, Barkham T, Yang H, Rénia L, Leo YS, Ng LF. Persistent arthralgia induced by Chikungunya virus infection is associated with interleukin-6 and granulocyte macrophage colony-stimulating factor. J Infect Dis. 2011 Jan 15;203(2):149-57. [PMC free article: PMC3071069] [PubMed: 21288813]

20.

Caglioti C, Lalle E, Castilletti C, Carletti F, Capobianchi MR, Bordi L. Chikungunya virus infection: an overview. New Microbiol. 2013 Jul;36(3):211-27. [PubMed: 23912863]

21.

Hua C, Combe B. Chikungunya Virus-Associated Disease. Curr Rheumatol Rep. 2017 Oct 05;19(11):69. [PubMed: 28983760]

22.

Madariaga M, Ticona E, Resurrecion C. Chikungunya: bending over the Americas and the rest of the world. Braz J Infect Dis. 2016 Jan-Feb;20(1):91-8. [PMC free article: PMC9425360] [PubMed: 26707971]

23.

Pakran J, George M, Riyaz N, Arakkal R, George S, Rajan U, Khader A, Thomas S, Abdurahman R, Sasidharanpillai S, Thumbayil L. Purpuric macules with vesiculobullous lesions: a novel manifestation of Chikungunya. Int J Dermatol. 2011 Jan;50(1):61-9. [PubMed: 21182504]

24.

Bandyopadhyay D, Ghosh SK. Mucocutaneous features of Chikungunya fever: a study from an outbreak in West Bengal, India. Int J Dermatol. 2008 Nov;47(11):1148-52. [PubMed: 18986446]

25.

Arpino C, Curatolo P, Rezza G. Chikungunya and the nervous system: what we do and do not know. Rev Med Virol. 2009 May;19(3):121-9. [PubMed: 19274635]

26.

Ulloa-Padilla JP, Dávila PJ, Izquierdo NJ, García-Rodríguez O, Jiménez IZ. Ocular Symptoms and Signs of Chikungunya Fever in Puerto Rico. P R Health Sci J. 2018 Jun;37(2):83-87. [PubMed: 29905918]

27.

Salceanu SO, Raman V. Recurrent chikungunya retinitis. BMJ Case Rep. 2018 Aug 27;2018 [PMC free article: PMC6119402] [PubMed: 30150331]

28.

Martínez-Pulgarín DF, Chowdhury FR, Villamil-Gomez WE, Rodriguez-Morales AJ, Blohm GM, Paniz-Mondolfi AE. Ophthalmologic aspects of chikungunya infection. Travel Med Infect Dis. 2016 Sep-Oct;14(5):451-457. [PubMed: 27238905]

29.

Mahendradas P, Ranganna SK, Shetty R, Balu R, Narayana KM, Babu RB, Shetty BK. Ocular manifestations associated with chikungunya. Ophthalmology. 2008 Feb;115(2):287-91. [PubMed: 17631967]

30.

Thiberville SD, Moyen N, Dupuis-Maguiraga L, Nougairede A, Gould EA, Roques P, de Lamballerie X. Chikungunya fever: epidemiology, clinical syndrome, pathogenesis and therapy. Antiviral Res. 2013 Sep;99(3):345-70. [PMC free article: PMC7114207] [PubMed: 23811281]

31.

Le Coupanec A, Tchankouo-Nguetcheu S, Roux P, Khun H, Huerre M, Morales-Vargas R, Enguehard M, Lavillette D, Missé D, Choumet V. Co-Infection of Mosquitoes with Chikungunya and Dengue Viruses Reveals Modulation of the Replication of Both Viruses in Midguts and Salivary Glands of Aedes aegypti Mosquitoes. Int J Mol Sci. 2017 Aug 04;18(8) [PMC free article: PMC5578098] [PubMed: 28777313]

32.

Jain J, Nayak K, Tanwar N, Gaind R, Gupta B, Shastri JS, Bhatnagar RK, Kaja MK, Chandele A, Sunil S. Clinical, Serological, and Virological Analysis of 572 Chikungunya Patients From 2010 to 2013 in India. Clin Infect Dis. 2017 Jul 01;65(1):133-140. [PubMed: 28379375]

33.

Panning M, Grywna K, van Esbroeck M, Emmerich P, Drosten C. Chikungunya fever in travelers returning to Europe from the Indian Ocean region, 2006. Emerg Infect Dis. 2008 Mar;14(3):416-22. [PMC free article: PMC2570846] [PubMed: 18325256]

34.

Kumar P, Pok KY, Tan LK, Angela C, Leo YS, Ng LC. Development and evaluation of baculovirus-expressed Chikungunya virus E1 envelope proteins for serodiagnosis of Chikungunya infection. J Virol Methods. 2014 Sep;206:67-75. [PubMed: 24880071]

35.

Loconsole D, Metallo A, De Robertis AL, Morea A, Quarto M, Chironna M. Seroprevalence of Dengue Virus, West Nile Virus, Chikungunya Virus, and Zika Virus in International Travelers Attending a Travel and Migration Center in 2015-2017, Southern Italy. Vector Borne Zoonotic Dis. 2018 Jun;18(6):331-334. [PMC free article: PMC5985901] [PubMed: 29683399]

36.

Simon F, Javelle E, Cabie A, Bouquillard E, Troisgros O, Gentile G, Leparc-Goffart I, Hoen B, Gandjbakhch F, Rene-Corail P, Franco JM, Caumes E, Combe B, Poiraudeau S, Gane-Troplent F, Djossou F, Schaerverbeke T, Criquet-Hayot A, Carrere P, Malvy D, Gaillard P, Wendling D., Société de pathologie infectieuse de langue francaise. French guidelines for the management of chikungunya (acute and persistent presentations). November 2014. Med Mal Infect. 2015 Jul;45(7):243-63. [PubMed: 26119684]

37.

Mahendradas P, Avadhani K, Shetty R. Chikungunya and the eye: a review. J Ophthalmic Inflamm Infect. 2013 Feb 11;3(1):35. [PMC free article: PMC3605073] [PubMed: 23514031]

38.

Parashar D, Paingankar MS, Kumar S, Gokhale MD, Sudeep AB, Shinde SB, Arankalle VA. Administration of E2 and NS1 siRNAs inhibit chikungunya virus replication in vitro and protects mice infected with the virus. PLoS Negl Trop Dis. 2013;7(9):e2405. [PMC free article: PMC3764232] [PubMed: 24040429]

39.

Subudhi BB, Chattopadhyay S, Mishra P, Kumar A. Current Strategies for Inhibition of Chikungunya Infection. Viruses. 2018 May 03;10(5) [PMC free article: PMC5977228] [PubMed: 29751486]

40.

Oliveira AF, Teixeira RR, Oliveira AS, Souza AP, Silva ML, Paula SO. Potential Antivirals: Natural Products Targeting Replication Enzymes of Dengue and Chikungunya Viruses. Molecules. 2017 Mar 22;22(3) [PMC free article: PMC6155337] [PubMed: 28327521]

41.

Audain G, Maher C. Prevention and Control of Worldwide Mosquito-Borne Illnesses: Nurses as Teachers. Online J Issues Nurs. 2017 Jan 31;22(1):5. [PubMed: 28488821]

42.

Silva NMD, Teixeira RAG, Cardoso CG, Siqueira Junior JB, Coelho GE, Oliveira ESF. Chikungunya surveillance in Brazil: challenges in the context of Public Health. Epidemiol Serv Saude. 2018 Sep 03;27(3):e2017127. [PubMed: 30183867]

43.

Moyes CL, Vontas J, Martins AJ, Ng LC, Koou SY, Dusfour I, Raghavendra K, Pinto J, Corbel V, David JP, Weetman D. Contemporary status of insecticide resistance in the major Aedes vectors of arboviruses infecting humans. PLoS Negl Trop Dis. 2017 Jul;11(7):e0005625. [PMC free article: PMC5518996] [PubMed: 28727779]

44.

Zhang Y, Wu J, Cheng X, Yang Y, Wang X, Zhao X, Wang X, Ouyang H, Ai J, Zhang W. Global resurgence of Chikungunya virus: outbreak drivers and emerging solutions. Emerg Microbes Infect. 2026 Dec;15(1):2603714. [PMC free article: PMC12777866] [PubMed: 41392880]

45.

Richardson JS, Anderson DM, Mendy J, Tindale LC, Muhammad S, Loreth T, Tredo SR, Warfield KL, Ramanathan R, Caso JT, Jenkins VA, Ajiboye P, Bedell L., EBSI-CV-317-004 Study Group. Chikungunya virus virus-like particle vaccine safety and immunogenicity in adolescents and adults in the USA: a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2025 Apr 19;405(10487):1343-1352. [PubMed: 40158526]

46.

Bonifay T, Lienne JF, Bagoée C, Santa F, Vesin G, Walter G, Nacher M, Vaserman N, Djossou F, Epelboin L. Prevalence and risk factors of post chikungunya rheumatic musculoskeletal disorders: a prospective follow-up study in French Guiana. Eur J Clin Microbiol Infect Dis. 2018 Nov;37(11):2159-2164. [PubMed: 30120648]

47.

Silva JVJ, Ludwig-Begall LF, Oliveira-Filho EF, Oliveira RAS, Durães-Carvalho R, Lopes TRR, Silva DEA, Gil LHVG. A scoping review of Chikungunya virus infection: epidemiology, clinical characteristics, viral co-circulation complications, and control. Acta Trop. 2018 Dec;188:213-224. [PMC free article: PMC7092809] [PubMed: 30195666]

48.

de Souza WM, Fumagalli MJ, de Lima STS, Parise PL, Carvalho DCM, Hernandez C, de Jesus R, Delafiori J, Candido DS, Carregari VC, Muraro SP, Souza GF, Simões Mello LM, Claro IM, Díaz Y, Kato RB, Trentin LN, Costa CHS, Maximo ACBM, Cavalcante KF, Fiuza TS, Viana VAF, Melo MEL, Ferraz CPM, Silva DB, Duarte LMF, Barbosa PP, Amorim MR, Judice CC, Toledo-Teixeira DA, Ramundo MS, Aguilar PV, Araújo ELL, Costa FTM, Cerqueira-Silva T, Khouri R, Boaventura VS, Figueiredo LTM, Fang R, Moreno B, López-Vergès S, Mello LP, Skaf MS, Catharino RR, Granja F, Martins-de-Souza D, Plante JA, Plante KS, Sabino EC, Diamond MS, Eugenin E, Proença-Módena JL, Faria NR, Weaver SC. Pathophysiology of chikungunya virus infection associated with fatal outcomes. Cell Host Microbe. 2024 Apr 10;32(4):606-622.e8. [PMC free article: PMC11018361] [PubMed: 38479396]

49.

Huits R, De Kort J, Van Den Berg R, Chong L, Tsoumanis A, Eggermont K, Bartholomeeusen K, Ariën KK, Jacobs J, Van Esbroeck M, Bottieau E, Cnops L. Chikungunya virus infection in Aruba: Diagnosis, clinical features and predictors of post-chikungunya chronic polyarthralgia. PLoS One. 2018;13(4):e0196630. [PMC free article: PMC5927412] [PubMed: 29709007]

50.

Sharma SK, Jain S. Chikungunya: A rheumatologist's perspective. Int J Rheum Dis. 2018 Mar;21(3):584-601. [PubMed: 29431292]

51.

Brito C, Falcão MB, de Albuquerque MFPM, Cerqueira-Silva T, Teixeira MG, Franca RFO. Chikungunya: From Hypothesis to Evidence of Increased Severe Disease and Fatalities. Viruses. 2025 Jan 03;17(1) [PMC free article: PMC11768798] [PubMed: 39861851]

52.

Runowska M, Majewski D, Niklas K, Puszczewicz M. Chikungunya virus: a rheumatologist's perspective. Clin Exp Rheumatol. 2018 May-Jun;36(3):494-501. [PubMed: 29533749]

53.

Schwameis M, Buchtele N, Wadowski PP, Schoergenhofer C, Jilma B. Chikungunya vaccines in development. Hum Vaccin Immunother. 2016 Mar 03;12(3):716-31. [PMC free article: PMC4964651] [PubMed: 26554522]

54.

Cai L, Hu X, Liu S, Wang L, Lu H, Tu H, Huang X, Tong Y. The research progress of Chikungunya fever. Front Public Health. 2022;10:1095549. [PMC free article: PMC9870324] [PubMed: 36699921]

Disclosure: Jafet Ojeda Rodriguez declares no relevant financial relationships with ineligible companies.

Disclosure: Anthony Haftel declares no relevant financial relationships with ineligible companies.

Disclosure: J Walker, III declares no relevant financial relationships with ineligible companies.